EP3452069A4 - Vecteur vaccinal de levure comprenant des polypeptides immunostimulants et antigéniques et ses procédés d'utilisation - Google Patents

Vecteur vaccinal de levure comprenant des polypeptides immunostimulants et antigéniques et ses procédés d'utilisation Download PDF

Info

Publication number
EP3452069A4
EP3452069A4 EP17793221.7A EP17793221A EP3452069A4 EP 3452069 A4 EP3452069 A4 EP 3452069A4 EP 17793221 A EP17793221 A EP 17793221A EP 3452069 A4 EP3452069 A4 EP 3452069A4
Authority
EP
European Patent Office
Prior art keywords
methods
same
vector including
vaccine vector
antigenic polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17793221.7A
Other languages
German (de)
English (en)
Other versions
EP3452069A1 (fr
Inventor
Billy Hargis
Leona Nicole CALHOUN
Luc Berghman
Lisa Bielke
Olivia B. FAULKNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arkansas
Texas A&M University System
Original Assignee
University of Arkansas
Texas A&M University System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Arkansas, Texas A&M University System filed Critical University of Arkansas
Publication of EP3452069A1 publication Critical patent/EP3452069A1/fr
Publication of EP3452069A4 publication Critical patent/EP3452069A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
EP17793221.7A 2016-05-03 2017-05-03 Vecteur vaccinal de levure comprenant des polypeptides immunostimulants et antigéniques et ses procédés d'utilisation Pending EP3452069A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662331044P 2016-05-03 2016-05-03
PCT/US2017/030764 WO2017192671A1 (fr) 2016-05-03 2017-05-03 Vecteur vaccinal de levure comprenant des polypeptides immunostimulants et antigéniques et ses procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP3452069A1 EP3452069A1 (fr) 2019-03-13
EP3452069A4 true EP3452069A4 (fr) 2020-02-12

Family

ID=60203263

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17793221.7A Pending EP3452069A4 (fr) 2016-05-03 2017-05-03 Vecteur vaccinal de levure comprenant des polypeptides immunostimulants et antigéniques et ses procédés d'utilisation

Country Status (12)

Country Link
US (2) US10682398B2 (fr)
EP (1) EP3452069A4 (fr)
JP (3) JP7467027B2 (fr)
KR (2) KR20190015712A (fr)
AR (1) AR108688A1 (fr)
AU (2) AU2017260323B2 (fr)
BR (1) BR112018072592A2 (fr)
CA (1) CA3023144A1 (fr)
MX (1) MX2018013331A (fr)
SG (1) SG11201809686SA (fr)
TW (2) TWI843057B (fr)
WO (1) WO2017192671A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111277B2 (en) 2016-12-28 2021-09-07 Invvax, Inc. Influenza vaccines
EP3996731A4 (fr) * 2019-07-12 2023-07-12 Op-T Llc Peptides et méthodes de traitement de maladies
EP4135742A2 (fr) 2020-04-17 2023-02-22 Op-T Llc Peptides bioactifs et leurs méthodes d'utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014127185A1 (fr) * 2013-02-14 2014-08-21 The Board Of Trustees Of The University Of Arkansas Compositions et procédés pour renforcer des réponses immunitaires vis-à-vis d'eimeria ou limiter une infection par eimeria

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU664360B2 (en) 1991-03-05 1995-11-16 Wellcome Foundation Limited, The Expression of recombinant proteins in attenuated bacteria
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
ES2227513T5 (es) 1991-10-25 2009-04-01 Immunex Corporation Citoquina novedosa.
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
EP0659086B1 (fr) 1992-09-04 1998-11-11 The University of Saskatchewan Nouveaux vaccins bacteriens utilisant des souches vaccinales de bacteries pathogenes
AU1059095A (en) 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
ES2179187T3 (es) 1995-03-01 2003-01-16 Immunex Corp Oriteuba qye se yba a cd40 para estimular una respuesta inmune.
WO1996040918A2 (fr) 1995-06-07 1996-12-19 Immunex Corporation Muteine de cd40l
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6306387B1 (en) 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
US20030045492A1 (en) 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2223225A1 (fr) 1997-11-28 1999-05-28 Canadian Red Cross Society Methode d'inhibition de la reaction immunitaire in vivo
AU2004199A (en) 1997-12-19 1999-07-12 Immunex Corporation Method for reducing susceptibility to hiv infection
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
IT1299583B1 (it) 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
BR9914479A (pt) 1998-09-04 2001-06-26 Creatogen Ag Mutantes sp12 de salmonella atenuada como carreadores antìgenos
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
IL144952A0 (en) 1999-04-16 2002-06-30 Hoffmann La Roche Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
EP1067194A1 (fr) 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vecteurs contenant des gènes codant pour CD40 et/ou CD40L, sous le contrôle du promoteur inductibles à cytokine, qui est un promoteur d'amyloide sérique à phase aigue humaine. Procédés de leur fabrication et leurs utilisations
EP1246643A4 (fr) 1999-10-14 2005-05-11 Jeffery A Ledbetter Vaccins a base d'adn codant pour un antigene associe a un domaine se liant a cd40
PT1112747E (pt) 1999-12-28 2004-10-29 Akzo Nobel Nv Vacina de salmonella que nao induz anticorpos contra flagelina ou flagelos
US7371392B2 (en) 2000-02-02 2008-05-13 The United States Of America As Represented By The Department Of Health And Human Services Cd40 ligand adjuvant for respiratory syncytial virus
ES2244617T3 (es) 2000-03-17 2005-12-16 Pharmacia & Upjohn Co Llc Vacunas a base de salmonelas en las cuales los genes ssa han sido inactivados.
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
AU2001273009A1 (en) 2000-06-26 2002-01-08 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
AU2002221780A1 (en) 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
SK15422003A3 (sk) 2001-05-15 2005-01-03 Research Institute North Shore-Long Island Jewish Použitie fragmentov HMG ako protizápalových činidiel
EP2330187B1 (fr) 2001-05-15 2016-07-27 Janssen Pharmaceuticals, Inc. Cellules T CD8 + spécifiques pour un peptide WVDNKTFSV qui sont spécifiquement cytotoxiques pour les cellules IgE-positif et des procédés de production.
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
JP2005511770A (ja) 2001-12-19 2005-04-28 アルケド バイオテック ゲーエムベーハー Ｈｍｇｂタンパク質およびｈｍｇｂタンパク質をコードする核酸の使用方法
EP1463755B1 (fr) 2001-12-21 2008-06-25 Immunex Corporation Polypeptides de recombinaison
KR100965026B1 (ko) 2002-02-13 2010-06-21 이뮤놀로지 래보러토리스 인코포레이티드 미생물 감염증을 치료하기 위한 조성물 및 방법
US6923958B2 (en) 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
EP2380440B1 (fr) 2002-04-15 2016-03-09 Washington University Atténuation régulée de vaccins vivants pour améliorer l'immunogénicité protectrice croisée
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US20060121047A1 (en) 2002-11-20 2006-06-08 Tracey Kevin J Use of hmgb polypetides for increasing immune responses
US20040141948A1 (en) 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
EP1569684A4 (fr) 2002-11-20 2006-08-02 Critical Therapeutics Inc Utilisation de fragments hmgb en tant qu'agents anti-inflammatoires
US20040156851A1 (en) 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
US20060014248A1 (en) 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050181994A1 (en) 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005025604A2 (fr) 2003-09-10 2005-03-24 The General Hospital Corporation Utilisation de hmgb et fragments de hmgb pour faire diminuer la reponse immunitaire specifique
WO2005026209A2 (fr) 2003-09-11 2005-03-24 Critical Therapeutics, Inc. Anticorps monoclonaux diriges contre hmgb1
WO2005035570A2 (fr) 2003-10-10 2005-04-21 Xencor, Inc. Nouveaux variants de la proteine cd40l
ES2358804T3 (es) 2003-11-21 2011-05-13 Ace Biosciences A/S Polipéptidos de campylobacter jejuni ubicados en superficie.
WO2005058950A2 (fr) 2003-12-11 2005-06-30 Sidney Kimmel Cancer Center Procedes pour generer une immunite a un antigene
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
WO2005103073A2 (fr) 2004-04-27 2005-11-03 Intercell Ag Antigenes de lambliase (diarrhee des voyageurs)
WO2005113598A2 (fr) 2004-05-21 2005-12-01 Xencor, Inc. Membres de la superfamille des tnf avec immunogenicite modifiee
EP1768698A4 (fr) 2004-06-17 2009-01-28 Medimmune Inc Compositions immunogeniques comprenant des polypeptides hmgb1
AU2005321630A1 (en) * 2004-07-02 2006-07-06 Metanomics Gmbh Process for the production of fine chemicals
WO2006012373A2 (fr) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Polytherapies hmgb
JP5269412B2 (ja) 2004-10-07 2013-08-21 アルゴス セラピューティクス，インコーポレイティド 成熟樹状細胞組成物およびその培養方法
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
GB0423681D0 (en) 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
WO2006105972A1 (fr) 2005-04-07 2006-10-12 Universite Libre De Bruxelles Organisme transgenique exprimant cd40l et utilisations de celui-ci
WO2006130525A2 (fr) 2005-05-31 2006-12-07 Sidney Kimmel Cancer Center Procedes d'immunotherapie de cancer
WO2007011606A2 (fr) 2005-07-18 2007-01-25 Critical Therapeutics, Inc. Hmgb1 et etats inflammatoires de la peau
PL1949913T3 (pl) 2005-10-07 2010-10-29 Proyecto De Biomedicina Cima S L Immunostymulująca kombinacja do profilaktyki i leczenia wirusowego zapalenia wątroby typu c
US9533036B2 (en) 2005-11-07 2017-01-03 Microvax, Llc Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein
WO2007054658A1 (fr) 2005-11-14 2007-05-18 King's College London Contrôle de réponses immunitaires
WO2007130725A2 (fr) 2006-02-06 2007-11-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Utilisation de hmgb1 en protection contre les lésions de reperfusion de l'ischémie
CU23576A1 (es) 2006-02-28 2010-09-30 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la influenza aviar
WO2007103048A2 (fr) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Conjugués de protéine agoniste de tlr (flagelline)/agoniste de cd40/ antigène et d'adn et leur utilisation pour induire un renforcement synergique de l'immunité
WO2007106073A2 (fr) 2006-03-02 2007-09-20 University Of Massachusetts agents pathogenes modifies a utiliser en tant que vaccins
CN101512337A (zh) * 2006-05-04 2009-08-19 阿布马克西斯公司 跨物种与多物种展示系统
CA2659275C (fr) 2006-07-27 2017-01-10 Ligocyte Pharmaceuticals, Inc. Particules de type virus grippal chimerique
CN104278014A (zh) 2006-08-09 2015-01-14 米迪缪尼有限公司 流感血凝素和神经氨酸酶变体
PL2066339T3 (pl) 2006-09-18 2015-02-27 Univ Arkansas Kompozycje i sposoby zwiększania odpowiedzi immunologicznych
WO2008055069A2 (fr) * 2006-10-27 2008-05-08 Dow Agrosciences Llc Vaccin contre l'entérite nécrosante de la volaille, qui comprend un antigène d'alpha-toxine de clostridium perfringens muté et procédés de production du vaccin
US20100292309A1 (en) 2007-03-08 2010-11-18 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
WO2009009215A2 (fr) 2007-05-02 2009-01-15 Emory University Amélioration d'incorporation de glycoprotéine dans des particules de type viral
NZ585776A (en) 2007-10-30 2012-07-27 Univ Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
CA3051748C (fr) 2007-11-01 2022-07-12 The Board Of Trustees Of The University Of Arkansas Compositions et procedes pour amplifier des reponses immunitaires a l'eimeria
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis
AU2009240884B8 (en) 2008-04-30 2014-03-06 Genomix Co., Ltd. Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
KR101651304B1 (ko) 2008-09-11 2016-08-25 앵스티띠 파스퇴르 Ｈｍｇｂ1 의존적인 ｈｉｖ-1 복제 및 지속감염 촉발의 조절에 의한 인간 면역결핍 바이러스 감염의 모니터링 및 억제
US8163281B2 (en) 2009-03-04 2012-04-24 The Regents Of The University Of Michigan Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
MX341775B (es) 2010-01-21 2016-09-02 The Texas A&M Univ System * Vectores para vacunas y metodos para potenciar respuestas inmunes.
ES2413437T3 (es) 2010-03-10 2013-07-16 Institut Pasteur HMGB1 y anticuerpos anti-HMGB1 en pacientes infectados por VIH especialmente con trastornos neurológicos
US8865653B2 (en) 2010-04-22 2014-10-21 Institut Gustave Roussy Method of treatment for immunogenic treatment resistant cancer
KR102008120B1 (ko) * 2010-06-09 2019-08-07 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 캄필로박터 감염을 감소시키기 위한 백신 및 방법
WO2014028776A1 (fr) 2012-08-15 2014-02-20 Zyngenia, Inc. Complexes multispécifiques monovalents et multivalents et leurs utilisations
CN109364244B (zh) 2012-10-29 2022-04-29 阿肯色大学评议会 黏膜佐剂和递送系统
JP6530742B2 (ja) * 2013-03-15 2019-06-12 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 腸内病原体の免疫応答を強化する組成物及び方法
EA201692375A1 (ru) 2014-06-05 2017-04-28 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас Антитело-опосредованные вакцины и способы их применения для получения быстрых зрелых иммунных ответов

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014127185A1 (fr) * 2013-02-14 2014-08-21 The Board Of Trustees Of The University Of Arkansas Compositions et procédés pour renforcer des réponses immunitaires vis-à-vis d'eimeria ou limiter une infection par eimeria

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WASILENKO JAMIE L ET AL: "Cell surface display of highly pathogenic avian influenza virus hemagglutinin on the surface of Pichia pastoris cells using alpha-agglutinin for production of oral vaccines.", BIOTECHNOLOGY PROGRESS, vol. 26, no. 2, March 2010 (2010-03-01), pages 542 - 547, XP002796532, ISSN: 1520-6033 *

Also Published As

Publication number Publication date
TWI758288B (zh) 2022-03-21
AU2017260323B2 (en) 2023-11-16
US20170319671A1 (en) 2017-11-09
MX2018013331A (es) 2019-06-10
JP7467027B2 (ja) 2024-04-15
JP2019514971A (ja) 2019-06-06
US20200297825A1 (en) 2020-09-24
US11382962B2 (en) 2022-07-12
CA3023144A1 (fr) 2017-11-09
BR112018072592A2 (pt) 2019-04-16
SG11201809686SA (en) 2018-11-29
JP2024023648A (ja) 2024-02-21
EP3452069A1 (fr) 2019-03-13
AU2017260323A1 (en) 2018-12-20
AU2023255055A1 (en) 2023-11-16
JP2022040389A (ja) 2022-03-10
TW202224701A (zh) 2022-07-01
KR20190015712A (ko) 2019-02-14
WO2017192671A1 (fr) 2017-11-09
TW201803590A (zh) 2018-02-01
US10682398B2 (en) 2020-06-16
AR108688A1 (es) 2018-09-19
TWI843057B (zh) 2024-05-21
KR20230070521A (ko) 2023-05-23

Similar Documents

Publication Publication Date Title
EP3416679A4 (fr) Vaccins contre des agents pathogènes et leurs procédés de production et d'utilisation
IL269830B1 (en) Peptide-based compositions, methods of production, and uses thereof for inducing an immune response
IL262366A (en) Immunomodulatory proteins and cd80 variants and their uses
IL268781A (en) Immunomodulatory proteins and variants of CD80 and their uses
EP3678677A4 (fr) Polypeptides de présentation d'antigène et leurs procédés d'utilisation
EP3538561A4 (fr) Polypeptides de variant guidés par arn et leurs procédés d'utilisation
EP3416634A4 (fr) Agents immunomodulateurs et leurs procédés d'utilisation
EP3509615A4 (fr) Peptides stables et leurs procédés d'utilisation
EP3646883A4 (fr) Nouveau vaccin antitumoral et son utilisation
EP3413926A4 (fr) Vaccination et immunothérapie contre le vih
EP3207142A4 (fr) Souches vaccinales de listeria de recombinaison et méthodes d'utilisation desdites souches dans l'immunothérapie anticancéreuse
EP3423438A4 (fr) Protéines de mouvement de phytovirus et leurs procédés d'utilisation
EP3134510A4 (fr) Souches de listeria utilisées comme vaccin recombinant et procédé de production
EP3707152A4 (fr) Peptides hétéroclitiques immunogènes issus de protéines associées au cancer et procédés d'utilisation de ces peptides
EP3200831A4 (fr) Vaccins possédant un antigène et une interleukine-21 en tant qu'adjuvant
EP3436476A4 (fr) Anticorps anti-ryk et leurs procédés d'utilisation
EP3481854A4 (fr) Compositions immunogènes à base de listeria comprenant des antigènes de protéine tumorale de wilms et procédés d'utilisation correspondants
EP3615060A4 (fr) Peptides antigéniques de vhs et vaccins protéiques de vhs
EP3717511A4 (fr) Vaccins contre le virus zika, compositions immunogènes et leurs procédés d'utilisation
EP3347045A4 (fr) Anticorps générés par le vaccin mva-gh/gl-pc neutralisant le pouvoir infectieux du cytomégalovirus humain et procédés associés
EP3730620A4 (fr) Vaccin antigénique à immunisation croisée et son procédé de préparation
EP3452069A4 (fr) Vecteur vaccinal de levure comprenant des polypeptides immunostimulants et antigéniques et ses procédés d'utilisation
EP3856895A4 (fr) Vaccins autologues bihapténisés et leurs utilisations
EP3538541A4 (fr) Préparation et utilisation de ginsénosides et de peptides de type ginsénoside
EP3601572A4 (fr) Construction d'expression de protéine et procédés associés

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/39 20060101ALI20191218BHEP

Ipc: A61P 31/04 20060101ALI20191218BHEP

Ipc: A61K 39/00 20060101ALI20191218BHEP

Ipc: A61P 33/00 20060101ALI20191218BHEP

Ipc: A61K 36/06 20060101AFI20191218BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20200113

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40003458

Country of ref document: HK